Systemic lupus erythematosus-associated acute transverse myelitis: manifestations, treatments, outcomes, and prognostic factors in 20 patients. (January 2015)

• Record Type: Journal Article
• Authors: Saison, J; Costedoat-Chalumeau, N; Maucort-Boulch, D; Iwaz, J; Marignier, R; Cacoub, P; Vital-Durand, D; Hot, A; Tebib, J; Aumaitre, O; Schleinitz, N; Sarrot-Reynauld, F; Broussolle, C; Sève, P
• Is Part Of: Lupus. Volume 24:Number 1(2015)
• Page Start: 74
• Page End: 81
• Publication Date: 2015-01
• Subjects: Systemic lupus erythematosus -- antiphospholipid syndrome -- myelitis -- cyclophosphamide -- hydroxychloroquine -- neuromyelitis optica; Systemic lupus erythematosus -- Periodicals; 616.772005
• DOI: 10.1177/0961203314547795
• Languages: English
• ISSNs: 0961-2033

Abstract

Background: Transverse myelitis is a rare complication of systemic lupus erythematosus (SLE). This retrospective multicentre study identifies the prognostic factors in a relatively large patient series. Patients and methods: Twenty patients fulfilled the SLE criteria of the ACR classification and the Transverse Myelitis Consortium Working Group. A severe neurological flare was defined as muscle strength grade <3/5 in more than half the muscle groups at the motor neurological level. Inability to run or another significant ambulation-unrelated disability was considered as 'unfavourable neurological outcome'. Results: Myelitis was the first SLE symptom in 12 patients; in the eight others, it occurred 8.6 years (median delay) after SLE onset. Eleven patients presented severe neurological impairments. The treatment included corticosteroids in all patients associated with intravenous cyclophosphamide in 11 and/or hydroxychloroquine in 14. Unfavourable outcomes were observed in 53% of the patients at six months and in 28% at end of follow-up (median: 5.9 years). An initial severe neurological impairment and no cyclophosphamide use were associated with unfavourable neurological outcomes at six months and at end of follow-up, respectively. Conclusion: Transverse myelitis may reveal SLE or occur more than 10 years after SLE diagnosis. The initial severity of the neurological flare (with paraplegia) is the main prognostic marker. The study provides arguments for cyclophosphamide use.